PD-1、PD-L1在弥漫大B细胞淋巴瘤组织中的差异性表达及其临床意义

金静霞; 郑翠苹; 陈丽雅; 叶琼; 吴圣豪

doi:10.13201/j.issn.1004-2806.2018.01.008

PD-1、PD-L1在弥漫大B细胞淋巴瘤组织中的差异性表达及其临床意义

- 温州市中心医院(浙江温州, 325000)
基金项目:
省科技厅课题(No:2014C33159)

详细信息

通讯作者: 郑翠苹,E-mail:cuipingzheng@163.com

中图分类号: R733.4

收稿日期: 2017-08-24

The differential expression levels and clinical significance of PD-1 and PD-L1 in tumor tissues of diffuse large B cell lymphoma

- Department of Hematology, Wenzhou Central Hospital, Theorem Clinical College, Wenzhou Medical University, Wenzhou, 325000, China

More Information

Corresponding author: ZHENG Cuiping, E-mail: cuipingzheng@163.com

Received Date: 24 August 2017

摘要

摘要: 目的:探讨程序性死亡因子-1(PD-1)、程序性死亡配体-1(PD-L1)在弥漫大B细胞淋巴瘤(DLBCL)中的表达及其临床意义。方法:采用免疫组织化学方法检测50例初诊DLBCL组织(DLBCL组)和45例淋巴结良性增生病变组织(对照组)中PD-1、PD-L1蛋白的表达情况,并分析PD-1及PD-L1的表达与临床病理特征的关系。结果:DLBCL组中PD-1、PD-L1的阳性表达率均显著高于对照组(58.00%∶24.44%,64.00%∶28.89%,均P<0.05)。DLBCL组中PD-1表达与临床病理特征均无明显相关性;而PD-L1表达与B症状、EBV感染、肿瘤分期及病理分型均有明显相关性(均P<0.05)。PD-1阳性组中PD-L1表达率更高(82.76%∶38.10%,P<0.05)。结论:PD-L1在DLBCL组织中高表达,并与分期、病理分型、B症状及EBV感染相关。推测PD-L1的表达可能是DLBCL的一个不良预后因子,以PD-1/PD-L1信号通路为靶点的治疗有望成为难治性DLBCL的潜在方案。
- 弥漫大B细胞淋巴瘤 /
- 程序性死亡因子-1 /
- 程序性死亡配体-1 /
- 预后
Abstract: Objective:To investigate the expression levels and clinical significance of programmed cell death factor-1 (PD-1) and programmed cell death 1 ligand (PD-L1) in diffuse large B cell lymphoma (DLBCL).Method:Immunohistochemistry was used to detect expression levels of PD-1 and PD-L1 in DLBCL (test group,n=50) and benign proliferative lesions of lymph node tissues (control group,n=45).The correlation of PD-1 and PD-L1 expressions with clinicopathological characteristics were analyzed.Result:The expression levels of PD-1 and PD-L1 were significantly higher in DLBCL group than those in control group (58.00% vs 24.44%,64.00% vs 28.89%,P<0.05).In patients with DLBCL,the expression of PD-1 showed no significant correlation with clinicopathological variables,but the expression of PD-L1 showed significant correlation with B symptoms,EBV infection,tumor stage and pathological classification (P<0.05).The expression of PD-L1 was much higher in DLBCL with the positive expression of PD-1 (82.76% vs 38.10%,P<0.05).Conclusion:There is high expression level of PD-L1 in DLBCL,which is correlated with stage,pathological classification,B symptoms and EBV infection.The expression level of PD-L1 can be used as a poor prognostic factor for DLBCL,and PD-1/PD-L1 pathway-targeted immunotherapy may have therapeutic potential in refractory DLBCL.
- diffuse large B cell lymphoma /
- PD-1 /
- PD-L1 /
- prognosis

HTML全文

参考文献(27)

[1]	Sabattini E, Bacci F, Sagramoso C, et al.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[M]//WHO classification of tumours of haematopoietic and lymphoid tissues.International Agency for Research on Cancer, 2008:83-87.
[2]	Coiffier B, Lepage E, Brière J, et al.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J].N Engl J Med, 2002, 346:235-242.
[3]	Habermann TM, Weller EA, Morrison VA, et al.Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large Bcell lymphoma[J].J Clin Oncol, 2006, 24:3121-3127.
[4]	Coiffier B, Thieblemont C, Van Den Neste E, et al.Long-term outcome of patients in the LNH-98.5trial, the first randomized study comparing rituximabCHOP to standard CHOP chemotherapy in DLBCL patients:a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J].Blood, 2010, 116:2040-2045.
[5]	陈艳欣, 郑晓云, 刘庭波, 等.利妥昔单抗联合CHOP与单用CHOP方案治疗初治弥漫大B细胞淋巴瘤疗效及安全性对比[J].临床血液学杂志, 2015, 28 (9):760-763.
[6]	宾燕成, 张华, 李虎生, 等.利妥昔单抗联合GDP方案治疗复发难治性弥漫大B细胞淋巴瘤的疗效观察[J].临床血液学杂志, 2015, 28 (9):764-766.
[7]	Keir ME, Butte MJ, Freeman GJ, et al.PD-1and its ligands in tolerance and immunity[J].Annu Rev Immunol, 2008, 26:677-704.
[8]	Freeman GJ, Long AJ, Iwai Y, et al.Engagement of the PD-1immunoinhibitory receptor by a novel B7family member leads to negative regulation of lymphocyte activation[J].J Exp Med, 2000, 192:1027-1034.
[9]	Chen L, Flies DB.Molecular mechanisms of T cell costimulation and co-inhibition[J].Nat Rev Immunol, 2013, 13:227-242.
[10]	Kim JR, Moon YJ, Kwon KS, et al.Tumor infiltrating PD1-positive lymphocytes and the expression of PDL1predict poor prognosis of soft tissue sarcomas[J].PLoS one, 2013, 8:e82870-e82870.
[11]	Atanackovic D, Luetkens T, Kr9ger N.Coinhibitory molecule PD-1as a potential target for the immunotherapy of multiple myeloma[J].Leukemia, 2014, 28:993-1000.
[12]	Topalian SL, Hodi FS, Brahmer JR, et al.Safety, activity, and immune correlates of anti-PD-1antibody in cancer[J].N Engl J Med, 2012, 2012:2443-2454.
[13]	Mu CY, Huang JA, Chen Y, et al.High expression of PD-L1in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J].Med Oncol, 2011, 28:682-688.
[14]	Green MR, Monti S, Rodig SJ, et al.Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma[J].Blood, 2010, 116:3268-3277.
[15]	吴圣, 邵婧怡, 王芳, 等.PD-L1和PD-1在胃癌组织中的表达及其临床意义[J].安徽医科大学学报, 2015, 50 (6):821-825.
[16]	马薇, 罗殿中, 陈源, 等.PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J].实用医学杂志, 2011, 27 (9):1551-1553.
[17]	Kwon D, Kim S, Kim P, et al.Clinicopathological analysis of programmed cell death 1and programmed cell death ligand 1expression in the tumour microenvironments of diffuse large B cell lymphomas[J].Histopathology, 2015, 68:1079-1089.
[18]	Kiyasu J, Miyoshi H, Hirata A, et al.Expression of programmed cell death ligand 1is associated with poor overall survival in patients with diffuse large B-cell lymphoma[J].Blood, 2015, 126:2193-2201.
[19]	Kataoka K, Shiraishi Y, Takeda Y, et al.Aberrant PDL1expression through 3'-UTR disruption in multiple cancers[J].Nature, 2016, 534:402-406.
[20]	Green MR, Rodig S, Juszczynski P, et al.Constitutive AP-1activity and EBV infection induce PD-L1in Hodgkin lymphomas and posttransplant lymphoproliferative disorders:implications for targeted therapy[J].Clin Cancer Res, 2012, 18:1611-1618.
[21]	Fang W, Zhang J, Hong S, et al.EBV-driven LMP1and IFN-γup-regulate PD-L1in nasopharyngeal carcinoma:implications for oncotargeted therapy[J].Oncotarget, 2014, 5:12189-12202.
[22]	Iwai Y, Terawaki S, Honjo T.PD-1blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells[J].Int Immunol, 2005, 17:133-144.
[23]	Chen BJ, Chapuy B, Ouyang J, et al.PD-L1expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies[J].Clin Cancer Res, 2013, 19:3462-3473.
[24]	Lenz G, Wright G, Dave SS, et al.Stromal gene signatures in large-B-cell lymphomas[J].N Engl J Med, 2008, 359:2313-2323.
[25]	Taube JM, Klein A, Brahmer JR, et al.Association of PD-1, PD-1ligands, and other features of the tumor immune microenvironment with response to anti-PD-1therapy[J].Clin Cancer Res, 2014, 20:5064-5074.
[26]	Herbst RS, Soria JC, Kowanetz M, et al.Predictive correlates of response to the anti-PD-L1antibody MPDL3280Ain cancer patients[J].Nature, 2014, 515:563-567.
[27]	Armand P, Nagler A, Weller EA, et al.Disabling immune tolerance by programmed death-1blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma:results of an international phase II trial[J].J Clin Oncol, 2013, 31:4199-4206.